Free Trial
NASDAQ:ITOS

iTeos Therapeutics Q2 2025 Earnings Report

iTeos Therapeutics logo
$10.12 +0.02 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$10.12 0.00 (-0.05%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.94
Beat/Miss
N/A
One Year Ago EPS
N/A

iTeos Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iTeos Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

iTeos Therapeutics Earnings Headlines

Q3 EPS Estimates for iTeos Therapeutics Lifted by Wedbush
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More iTeos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iTeos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your email.

About iTeos Therapeutics

iTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

View iTeos Therapeutics Profile

More Earnings Resources from MarketBeat